GALT, LJPC
GALT is going after the same anti-galectin pathway that LJPC is going after. LJPC is further along in their clinical trials and going after CKD instead of NASH.
Its amazing the valuation difference here. My only guessES as to why are:
1) the NASH indication is a hot indication b/c of the ICPT skyrocket after good results and the question surrounding their history (as highlighted by the hit piece from The Street).
IF phase 2 results come back positive (in March), the potential of a multi-bagger is very very high. Of course on the flip side, if the results arent good, it will tank hard.
The Baker Brothers being in this after looking at the data allows me to have comfort holding these shares. Hopefully we start getting a run into results soon.
Market Data 
Markets 
